• Rinvoq Shows Promise in Spine Disease

    2 monthes ago - By MedPageToday

    The oral selective JAK-1 inhibitor upadacitinib showed efficacy through 1 year among patients with ankylosing spondylitis in a phase II/III trial.
    During the extension phase of a trial known as SELECT-AXIS 1, a 40...
    Read more ...

     

  • Celiac Disease: Novel Oral Inhibitor May Block Intestinal Damage

    Celiac Disease: Novel Oral Inhibitor May Block Intestinal Damage

    2 monthes ago - By Medscape

    A randomized, phase 2 trial explored the safety and efficacy of ZED1227, a transglutaminase inhibitor, after 6 weeks at three doses.
    Medscape Medical News
    Read more ...